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 Abstract  
 Stimulated by the interest in developing gold compounds for treating cancer, gold ion– 
 angiotensin peptide interactions are investigated by mass spectrometry. Under the experimental 
 conditions used, the majority of gold ion–angiotensin peptide complexes contain gold in the 
 oxidation states I and III. Both ESI-MS and MALDI-TOF MS detect singly/multiply charged ions 
 for mononuclear/multinuclear gold-attached peptides, which are represented as [peptide+a Au 
 (I)+b Au(III)+(e - a -3b) H]e+, where a,b≥0 and e is charge. ESI-MS data shows singly/multiply 
charged ions of Au(I)-peptide and Au(III)-peptide complexes. This study reveals that MALDI- 
TOF MS mainly detects singly charged Au(I)-peptide complexes, presumably due to the 
 ionization process. The electrons in the MALDI plume seem to efficiently reduce Au(III) to Au(I). 
 MALDI also tends to enhance the higher polymeric forms of gold-peptide complexes regardless 
 of the laser power used. Collision-induced dissociation experiments of the mononuclear and 
 dinuclear gold-attached peptide ions for angiotensin peptides show that the gold ion (a soft acid) 
 binding sites are in the vicinity of Cys (a soft ligand), His (a major anchor of peptide for metal ion 
 chelation), and the basic residue Arg. Data also suggests that the abundance of gold-attached 
 peptides increases with higher gold concentration until saturation, after which an increase in 
 gold ion concentration leads to the aggregation and/or precipitation of gold-bound peptides. 
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Introduction 
 
Cisplatin is a platinum(II) containing chemotherapy drug 
proven to be an effective treatment for several types of solid 
tumors [1–3]. However, a large number of cancer patients 
develop cisplatin resistance and a number of side effects are 
commonly reported [1–3]. For this reason, considerable efforts 
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have been made to create new effective anticancer 
metallodrugs [4–7]. Since gold(III) ion is isoelec-tronic with 
platinum(II) ion and it forms square-planar complexes as in 
cisplatin, gold(III) compounds are explored for potential 
anticancer activities. A number of gold(III) complexes with 
ligands such as bipyridyls, dithiocarbamato, porphyrins, and 
quinolines, which display in vitro and in vivo potent anticancer 
activities and reduced systemic toxicity compared with the 
cisplatin, have been synthesized [4–17]. Small peptides such as 
S-phenylalanine-S-phenylalanine, glycyl-alaline, glycyl-
histidine, alanyl-phenylalanine, glycyl-S-serine, glycyl-alanyl-
alanine, glycyl-glycyl-histidine, and glycyl-glycyl-methyonyl-
glycyl-glycine are another class of ligands of gold(III) ion that 
have been investigated for development of potential anticancer 
drugs [18–24]. Although evidence [10, 11, 28] suggests that 
gold-based chemotherapy agents seem to induce 
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antiproliferative activities against tumor cells, the main 
biological targets and mechanisms responsible for gold-induced 
cytotoxicity are still largely unknown. However, the 
interactions between gold-based chemotherapy agents and 
proteins are believed to be involved in the antitumor activity 
[10, 11, 28]. Detailed information on the interaction between 
gold ions and peptides/proteins is needed to shed light on the 
mechanism of gold compounds’ anticancer activity and side 
effects and facilitate the design of gold-based anticancer 
agents. 
      With the development of gentle ionization techniques such 
as ESI [29, 30] and MALDI [31, 32] for transferring 
peptides/proteins into the gas phase without detrimental effects 
on their integrity, mass spectrometry has been used 
successfully to characterize metal cation (such as calcium, 
cadmium, cobalt, copper, iron, magnesium, mercury, nickel, 
potassium, sodium, and zinc) peptide/protein interactions [33–
46]. Data reveals some general findings such as various metal 
ions may interact differently to a peptide sequence [33, 47], and 
the metal cation–peptide/protein bond is believed to be 
noncovalent [33]. Many MS studies suggest that the Cu-peptide 
ions by MALDI is formed by a reductive process which 
produces primarily Cu(I)-peptide ions, whereas ESI process 
yields almost exclusively Cu(II)-peptide ions unless a solvable 
copper emitter is used [34]. Collision induced dissociation 
(CID), a well established tandem mass spectrometry 
experiment, which produces the information of the sequence 
and metal ion binding sites of a peptide, of Zn ion– and Cu 
ion–angiotensin peptide complexes [34, 41, 48] indicate that 
zinc and copper interaction sites are in the neighborhood of the 
His and Arg residues, respectively. In addition, there are some 
MS studies on the gold–protein complexes [14, 28, 33, 49–52], 
disulfide bridge cleavage of gold(I) cationized peptides [53, 
54], and characterization of synthetic pure gold–peptide 
complexes [21–27]. Data from gold-attached glutathione 
reductase or thioredoxin reductase probed by MALDI-TOF MS 
speculates that Cys residue is critical to their biological 
functions [14, 50]. However, X-ray crystal together with the 
ESI-MS studies show that the His residue of the enzyme 
cyclophilin is the gold ion binding site, despite the presence of 
four Cys thiol groups in the enzyme [54]. Results from gold 
bound human serum albumin and poly(ADP-ribose) 
polymerase by ESI-MS speculate that both Cys and His 
residues are involved in the gold ion binding [28, 51]. ESI-MS 
study on the Au(I)-somatostin complex shows that Au(I) 
incorporation into a disulfide bridge containing peptide is a 
promising way to effect selective dissociation of disulfide 
bonds [52]. In another study, ESI-MS is used to confirm the 
reaction product of a synthetic Au(III)–pentapeptide 
(GGMGG) complex [21]. The majority of these gold complex 
studies are all aimed at the binding between gold and sulfur. 
Clearly, systematic MS studies on simple Au–peptide 
complexes are needed to provide a basis for the another study, 
ESI-MS is used to confirm the reaction product of a synthetic 
Au(III)–pentapeptide (GGMGG) complex [21]. The majority 
of these gold complex studies are all aimed at the binding 
between gold and sulfur. Clearly, systematic MS studies on 
simple Au–peptide complexes are needed to provide a basis for 
the interpretation of the interaction between gold ion and 
peptide/protein. As a first step of our gold ion-peptide/protein 
complex investigation, gold complexes of human angiotensin I 
(Asp-Arg-Val-Tyr-Ile-His-Pro-Phe-His-Leu), human angioten-
sin II (Asp-Arg-Val-Tyr-Ile-His-Pro-Phe), CysAngiotensin II 
(Cys-Asp-Arg-Val-Tyr-Ile-His-Pro-Phe), human angiotensin 
IV (Val-Tyr-Ile-His-Pro-Phe), VYIHPFHL (Val-Tyr-Ile-His-
Pro-Phe-His-Leu), tripeptide CDR, and dipeptide DR are 
probed by both ESI and MALDI-TOF/TOF MS. These choices 
enable the evaluation of the interaction between gold ion and 
potential metal binding amino acid residues. In addition, due to 
peptides' smaller sizes, data analysis is much simpler. 
Furthermore, besides angiotensin availability, its interactions 
with other metals investigated by MS have been reported, 
which enable the direct comparison between gold ion and other 
metal interactions with angiotensin peptides. Note that 
angiotensin II is a peptide hormone that causes hypertension 
and has been shown to inhibit proliferation of several cell 
types. Results obtained here show that singly/multiply charged 
ions for the mononuclear and/or dinuclear gold-attached 
peptide are detected in each complex. More abundant 
formation of gold ion–angiotensin complexes are detected as 
compare to the complex formation of Zn ion and Cu ion. In 
addition, CID data reveals many possible gold ion binding sites 
in the vicinity of Cys, His, and Arg of peptides, which is 
somewhat different from Zn ion (His is the preferred anchoring 
site) [48] and Cu ion (Arg is the preferred anchoring) [34, 41]. 
 
Experimental 
 
Chemicals and Materials 
 
All chemicals and peptides were purchased from Sigma-
Aldrich Chemical Company (Saint Louis, MO, USA) and used 
without further purification. Peptides DR, CDR, and 
CDRVYIHPF (CysAngiotensin II) were synthesized inhouse 
by solid phase peptide synthesis (see Supplemental Material). 
Sequencing grade modified trypsin was obtained from Promega 
Corporation (Madison, WI, USA). 
 
 
Preparation of the Gold Ion–Peptide Complexes 
 
Gold ion–peptide complexes were prepared by mixing 2 mM 
aqueous solution of AuCl3 or AuCl with an equimolar amount 
of peptide at room temperature. Concentration of gold ion 
greater than ~10 mM tends to encourage the precipitation of 
angiotensin I. Gold ion-angiotensin IV and VYIHPF were 
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prepared by trypsin digestion of gold-angiotensin I and II, 
respectively (see Supplementary Material). 
 
Analysis of the Gold Ion–Peptide Complex by Mass 
Spectrometry 
 
Gold ion–peptide samples for MALDI-TOF and 
MALDITOF/TOF MS analyses were prepared by either mixing 
equal amount of gold ion–peptide solution with matrix solution 
(3–10 mg Cyano-4-hydroxycinnamic acid in 1 ml aqueous 
solution of 50% acetonitrile containing 0.1% TFA) or 
concentrating the gold ion–peptide complex with Millipore 
(Billerica, MA, USA) C18 ZipTips and then eluted with matrix 
solution. Applied Biosystems (Foster City, CA, USA) 
Voyager-DE PRO MALDI-TOF or 4700 Proteomics Analyzer 
MALDI-TOF/TOF MS equipped with a 337 nm pulsed 
nitrogen laser was used to analyze the samples. The mass 
spectrum was obtained using the delayed extraction positive-
ion linear and/or reflector modes by averaging 100 laser shots. 
Tandem MS (MALDI-TOF/TOF) experiments were conducted 
using collision energy of 1 kV with helium as the collision gas. 
External mass calibration was performed using the masses of a 
mixture of bradykinin fragments 1–7 at m/z 757.40, angiotensin 
II (human) at m/z 1046.54, P14R (synthetic peptide) at m/z 
1533.86, and adrenocorticotropic hormone fragment 18–39 
(human) at m/z 2465.20. Data explorer software and MS data 
analysis tools from Protein-Prospector (http://prospector.ucsf. 
edu/prospector/mshome.htm) or proteomicsToolkit (http://db. 
systemsbiology.net:8080/proteomics-Toolkit) were used to 
analyze the data. 
       For ESI-MS analysis, mass spectra were obtained using 
either a Thermo Electron (Waltham, MA, USA) LCQ-deca 
quadrupole ion trap mass spectrometer or LTQ FT ultra hybrid 
linear ion trap Fourier transform-ion cyclotron resonance (FT-
ICR) mass spectrometer in the electrospray positive mode. A 
mass accuracy of 1 ppm of the precursor ions is obtained with 
FT-MS. Sample was introduced into LCQ-deca quadrupole ion 
trap by direct infusion using a syringe pump with flow rate of 
10 µL/min. The FT-MS spectra were obtained by electrospray 
using a New Objective (Waltham, MA, USA) 4 µm glass tip 
static probe with standard coating at a flow rate of 40–100 
nL/min. 
       For HPLC-ESI-MS gold ion-peptide analysis, sample is 
injected onto an Agilent (Santa Clara, CA, USA) 2.1 mm SB-
C18 or 75 µm Zorbax SB300 C-18 reversed-phase column 
connected to a Dionex (Sunnyvale, CA, USA) Ultimate 3000 
HPLC system. The samples were separated using a binary 
solvent system consisting of A: 0.1% formic acid and 5% 
acetonitrile and B: 0.1% formic acid and 95% acetonitrile at 
flow rate of 200 µL/min or 200 nL/min. A gradient was run 
from 5% B to 60%B over 30 or 60 min. The mass spectrometer 
was operated in positive ion mode with the trap set to data 
dependent MS/MS acquisition mode. Peaks eluted from the LC 
column that had ions above 1000 arbitrary intensity units 
trigger the ion trap to isolate the ion and perform an MS/MS 
experiment scan after the MS full scan. The ICR cell was run 
with a resolution setting of 100,000 at m/z 400 over the range 
from m/z 200 to 2000. The MS was operated under the 
following conditions: capillary temperature 200 °C; sheath gas 
2 psi and spray voltage 2.0 kV. The Xcalibur software was 
used to analyze the data. 
 
Results and Discussion 
 
Au Ion–Angiotensin I Complexes 
 
MALDI-TOF MS (Figure 1) of the angiotensin I in reaction 
with 1mM gold ion shows predominately singly charged intact 
(m/z 1296.68; abundant), singly gold-attached [M+Au(I)]+ (m/z 
1492.65; most abundant), and doubly gold-attached [M+2Au(I) 
– H]+ (m/z 1688.62; less abundant) angiotensin I ions. Results 
are identical no matter which gold ion is used (either AuCl3 or 
AuCl). This observation in MALDI-TOF MS suggests that 
MALDI process suppresses the detection of oxidation state III 
and encourages the reduction of Au(III) to Au(I) by electrons in 
the MALDI plume [55]. Similar findings have been reported 
for Cu ion-peptide complexes [34]. Since Gold has only one 
stable naturally occurring isotope 197Au with atomic mass 
196.96654, the interpretation of the mass spectrum is relatively 
simpler. The formula that describes the stoichiometry of the 
singly charged gold-peptide complex detected by MALDI-TOF 
MS is given by [M+a Au(I)+(1-a) H]+, where a=1, 2. HCl 
adduct [54] of singly gold-attached (m/z 1528.65) and doubly 
gold-attached (m/z 1724.62) angiotensin I ions are also 
detected. In addition higher polymeric forms of gold-
angiotensin I complex (i.e., [aM+bAu(I)+(b -1) H]+, where 
a,b≥1), such as [2 M+Au(I)]+ at m/z 2790.33 and [2 M – 
3H+4Au(I)]+ at m/z 3376.24, are also detected with much lower 
intensities regardless of the laser power used. This result is 
consistent with the property of gold which has a tendency to 
form supramolecular architecture (aurophilicity) due to its 
unusually large relativistic 6 s-orbital stabilization (contraction) 
[56]. In addition, this observation is similar to the results of Cu 
ion–peptide complexes [34], which reports the detection of 
[peptide+xCu – (x – 1)H] (x=1–6) ions. Here, multiply charged 
ions are rarely detected due to the MALDI set-up (normal 
MALDI instead of laserspray ionization MALDI) that was used 
[57, 58]. Interestingly, doubly charged ion (m/z 746.83) of 
singly gold-attached angiotensin I (m/z 1492.65) is detected 
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Figure 1. MALDI-TOF of Angiotensin I in the presence of 1mM AuCl3. The matrix used for desorption is cyano-4- 
hydroxycinnamic acid 
 
with lower intensity. The relative abundance of the gold-
attached angiotensin I ion species compared with the intact ion 
depends on the concentration of the gold ion. It is directly 
proportional to the concentration of AuCl3/AuCl, becoming 
undetectable when the concentration of gold ion is lower than 
0.5 µM. However, at concentration of AuCl3 higher than 10 
mM, the solution turns cloudy. The MS signals become 
undetectable when the concentration of AuCl3 is higher than 
250 mM, indicating that the gold-bounded species aggregate or 
precipitate out of the solution. 
     ESI-MS (Figure 2, only relevant ions are shown) of the 
angiotensin I in reaction with 1mM AuCl3 shows predominately 
three kinds of ion species. (1) Intact angiotensin I ions (singly 
charged, m/z 1296.68; doubly charged m/z 648.84; triply 
charged, m/z 432.89). (2) Singly gold-attached angiotensin I 
ions [M+Au(I)+ (e – 1) H]e+ (singly charged, m/z 1492.65; 
doubly charged, m/z 746.83; triply charged, m/z 498.22) and 
[M+Au(III)+(e – 3) H]e+ (singly charged, m/z 1490.65; doubly 
charged, m/z 745.82; triply charged, m/z 497.55). (3) Doubly 
gold-attached angiotensin I ions [M+2Au(I)+(e – 2) H]e+ 
(singly charged, m/z 1688.62; doubly charged, m/z 844.81; 
triply charged, m/z 563.54), [M+Au(I)+Au(III)+ (e – 4) H]e+ 
(singly charged, m/z 1686.62; doubly charged, m/z 843.81; 
triply charged, m/z 562.87), and [M+Au(III)+Au(III)+ (e – 6) 
H]e+ (singly charged, m/z 1684.62; doubly charged, m/z 842.81; 
triply charged, m/z 562.21). Data shows the gold ions exist in 
oxidation states of III and I, indicating some reduction of 
Au(III) to Au(I). Also shown are HCl adduct of singly gold-
attached and doubly gold-attached angiotensin I ions and 
higher polymeric forms of gold-angiotensin I complexes (i.e., 
[aM+bAu(I)+cAu(III)+(e–b–3c)H]e+), such as [2 M+Au(III)]3+ 
at m/z 929.44 and [2 M+2Au(I,III) – H]3+ at m/z 944.76. Higher 
polymeric forms of gold-angiotensin I complexes are present at 
lower amount by ESI-MS than by MALDI-TOF MS. The 
relationship between relative abundance of the gold-attached 
ion species and concentration of AuCl3 is similar as in MALDI-
TOF MS data described above. However, concentrations of 
gold ion higher that 10 mM greatly suppress the ESI-MS 
signal. 
     ESI-MS (Figure 3, only relevant ions are shown) of the 
angiotensin I in reaction with 1 mM AuCl shows three major 
kinds of ion species. (1) Intact angiotensin I ions described in 
the previous paragraph. (2) Singly gold-attached angiotensin I 
ions [M+Au(I)+ (e – 1) H]e+ (singly charged, m/z 1492.65; 
doubly charged, m/z 746.83; triply charged, m/z 498.22). (3) 
Doubly gold-attached angiotensin I ions [M+ 2Au(I)+ (e – 2) 
H]e+ (singly charged, m/z 1688.62; doubly charged, m/z 844.81) 
and [M+Au(I)+Au(III)+ (e – 4) H]e+ (singly charged, m/z 
1686.62; doubly charged, m/z 843.80). The gold ion exists 
predominately in oxidation state of I. The detection of doubly 
gold-attached angiotensin I [M+Au (I)+Au(III)+ (e – 4) H]e+ 
indicates that some of the Au(I) disproportionate in aqueous 
solution to Au(III). The HCl adduct of gold-attached angioten- 
sin I complexes described in the previous paragraph are also 
observed. The relationship between relative abundance of the 
gold-attached ion species and concentration of AuCl is similar 
as in MALDI-TOF MS described above. 
     The fact that only gold ion in the oxidation state I is 
observed in MALDI-TOF MS indicates that MALDI process 
suppresses the detection and promotes the reduction of higher 
oxidation states. Additionally, due to the difference in the 
ionization process between MALDI (addition of matrix, drying 
of the sample, and desorption by a laser) and ESI, the former 
tends to encourage the detection of higher polymeric forms of 
gold-peptide complexes. The CID data of singly and multiply 
charged angiotensin I and gold-bound angiotensin I by 
MALDI-TOF/TOF (Figure 4) and ESI-MS/MS (see Figure S1 
in Supplementary Material) reveals detailed information 
regarding the binding between gold ion and angiotensin I. The 
nomenclature for CID fragment ions, chemical structure, and 
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Figure 2. The ESI–MS of angiotensin I in the presence of 1mM AuCl3. Expanded regions of peaks corresponding to (a) [M+Au]2+, 
(b) [M+Au]3+, (c) [M+2Au]2+ , and (d) [M+2Au]3+ ions 
 
Figure 3. The ESI-MS of angiotensin I in the presnece of 1mM 
AuCl. Expanded regions corresponding to (a) [M+Au]2+, (b) 
[M+Au]3+ , and (c) [M+2Au]2+ ions 
 
peptide sequence of angiotensin I can be found in 
Supplementary Material. Three major types of backbone bonds 
may be broken upon CID, leading to six homologous series of 
fragment ions (a, b, c, x, y, and z ions) [59–61]. The a-type, b-
type, and c-type fragment ions contain the N-terminus (N-
terminal fragment ions), whereas x-type, y-type, and z-type 
fragment ions contain the C-terminus (C-terminal fragment 
ions). Numerical subscripts indicate the position of the amino 
acid residues at the cleavage sites. Both ionization methods 
produce strong signals from b, y, and a ion series in addition to 
the ions formed by H2O, NH3, or CO loss. Several factors 
contribute to the efficacy of the identification of gold binding 
sites using the CID mass spectra. First, due to the large 
relativistic effect of gold [56], gold–peptide binding is 
relatively strong and survive the CID condition used here. 
Second, angiotensin I contains one Arg and two His basic 
residues equally distributed along the peptide chain, one Pro 
residue in the middle of the peptide chain, and one Asp residue. 
Note that peptide fragments containing basic residues 
(protonated preferentially and retain the charge) tend to 
dominate the CID mass spectrum, and the Pro residue in the 
peptide sequence tends to enhance the cleavage of the peptide 
bond n-terminal to it due to a higher basicity of the imide 
nitrogen. Additionally, cleavage at the c-terminus of Asp 
residue is favored because of protonation of the peptide bond 
by the Asp side-chain carboxyl group. The majority of the a, b, 
and y series are detected in this study, which facilitate the 
identification of the gold binding sites. Third, angiotensin I is a 
short peptide with 10 amino acid residues, which makes the 
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data interpretation relatively easy. The immonium ions (a 
singly side chain fragment formed by a combination of a-type 
and y-type cleavage) detected in MALDI-TOF/TOF 
unambiguously identified the presence of Arg (m/z 87, 100, and 
112), Asp (m/z 88), Ile/Leu (m/z 86), His (m/z 110 and 138), 
Phe (m/z 120), Pro (m/z 70), Tyr (m/z 136), and Val (m/z 72). 
Since the peptide contains Pro amino acid residue, enhanced 
signals from internal ions (double backbone cleavage of b type 
and y type; contain neither N-terminus nor C-terminus) and Y 
(y-2)-type ions are also detected. An abundant y9 ion at m/z 
1377 is detected, which corresponds to a 115 Da loss from the 
molecular ion. Considering the correlation between 
complementary b and y ions (yi + b10-i– 1= MH+), this mass 
difference is consistent with a b1 mass of 116 Da (Asp as the 
N-terminus). CID data shows that the singly gold-attached 
angiotensin I consists of three species. One species has the gold 
bonded to the basic residue Arg (e.g., b2, b4, and b5 ions in 
Figure 4a). The significance of the Arg residue in peptide-metal 
bonding has been reported on Arg containing peptide–metal ion 
interactions [41, 47]. The basic guanidinium group (pKa of 
12.48) of Arg and the conjugation between double bond and 
the nitrogen lone pairs most likely contribute to the binding 
between Arg and gold ion (soft acid). To further confirm the 
importance of the Arg residue in peptide-gold bonding, 
dipeptide DR is synthesized and its gold complex is probed by 
MS (see Figure S2 in Supplementary Material). Since there is 
only one gold binding site in DR (Arg at position 2), as  
 
 
 
 
 
 
 
expected, the CID data of the gold ion-dipeptide DR complex 
shows that the gold binding site is Arg and not the NH2-
terminal amino group or Asp. The other two species have the 
gold anchored at His residue at the sixth position (e.g., 
VYIH(Au), YIH(Au)P internal ions in Figure4a) or ninth 
position (e.g., b7 and b8 ions in Figure S1b in Supplementary 
Material), most likely through the N3 site of the His-imidazole 
ring (the major metal anchoring site beside sulfur of Cys) [21, 
26, 52, 62, 63]. Similar conclusions indicate that both His 
residues are involved in the metal binding has been reported on 
Zn–angiotensin I complexes [48]. Doubly gold-attached 
angiotensin I also shows three species [gold bonded through 
Arg and His at position 6 (e.g., a8, and y8 ions in Figure 4b), 
gold bonded through the Arg and His at position 9 (e.g., y5 ion 
in Figure 4b), and gold bonded through both His at positions 6 
and 9 (e.g., y5, y6, y7, and y8 ions in Figure 4b)]. Note that 
bidentate and/or tridentate coordination of gold ion by the Arg 
and two His residues is also possible structures from these 
results. The bidentate/tridentate complexes have been proposed 
to be the possible structures in previous studies on Cu- and Zn-
angiotensin complexes [34, 48]. In addition, many NMR and 
X-ray studies on simple Au-peptide complexes have proposed 
multidentate structures involving the amide nitrogen and the N-
terminal NH2 group in addition to the amino acid residues [21–
27]. 
     The angiotensin I solution containing gold ion is digested 
with trypsin to produce gold ion–VYIHPFHL complex.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. CID mass spectra (MALDI-TOF/TOF) of (a) [M+Au(I)]+ and (b) [M –H+2Au(I)]+ ions of angiotensin I 
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MALDI-TOF MS and CID mass spectra (MALDI-TOF/TOF 
MS) of intact and singly gold-attached VYIHPFHL are shown 
in Figure S3 in Supplementary Material. Since there are two 
gold binding sites in VYIHPFHL (His at positions 4 and 7), as 
expected, the data is in agreement with a mixture of two gold 
ion–VYIHPFHL species [gold bonded through the His at 
position 6 (e.g., y2, a4, b4, and b6 ions in Figure S3c in 
Supplementary Material) and 7 (e.g., y3, a5, and b5 ions in 
Figure S3c in Supplementary Material)]. Same evidence of the 
gold–VYIHPFHL interaction is provided in ESI-MS/MS CID 
mass spectra (see Figure S4 in Supplementary Material). 
Although preferential peptide bond cleavages near His, 
followed by Au attachment to the pieces, can also explain the 
observed fragmentation pattern, data here seems to rule out this 
possibility because there is no amino acid besides His that has a 
high metal affinity in both VYIHPFHL and VYIHPF (data 
presented below). 
 
 
Au Ion–Angiotensin II Complexes 
 
MALDI-TOF MS (Figure 5a) of the angiotensin II in reaction 
with either 1 mM AuCl3 or AuCl shows predominately singly 
charged intact (m/z 1046.54; abundant) and singly gold-
attached [M+Au(I)]+ (m/z 1242.50; less abundant) angiotensin 
II ions. The doubly gold-attached angiotensin II is barely 
detected at m/z 1438.47. The lower intensity for m/z 1438.47 
may stem from one less His residue (a major metal anchor site 
of a peptide) compared with angiotensin I. This observation is 
somewhat different from the Zn-angiotensin II complex, which 
shows no difference in the relative ratio of singly Zn-attached 
and doubly Zn-attached peptide between angiotensin I and 
angiotensin II [48]. ESI-MS (see Figure S5 in Supplementary 
Material) of the angiotensin II in reaction with either 1 mM 
AuCl3 or AuCl shows predominately the intact (singly charged, 
m/z 1046.54; doubly charged, m/z 523.77; triply charged, m/z 
349.52), singly gold-attached [M+Au(III)+(e – 3) H]e+ (singly 
charged, m/z 1240.50; doubly charged, m/z 620.75), and doubly 
gold-attached [M – H+2Au(I,III)]+ (singly charged, m/z 
1436.47) angiotensin II. Interestingly, the gold ion exists 
predominately in oxidation state of III in ESI-MS for singly 
gold-attached angiotensin II no matter which gold ion is used. 
Angiotensin II in the ESI condition seems to stabilize the 
highly oxidative gold(III) and promotes the disproportion of 
Au(I) to Au(III). The relationship between relative abundance 
of the gold-attached ion species and concentration of AuCl3 or 
AuCl is similar as in angiotensin I described above.  
     The binding sites between gold and angiotensin II is 
revealed by CID mass spectra of singly and multiply charged 
singly gold-bound, and doubly gold-bound angiotensin II by 
MALDI-TOF/TOF (Figure 5b and c) or ESI- MS/MS (see 
Figure S6 in Supplementary Material). Since there is one less 
His residue in angiotensin II than angiotensin I, as expected, 
data shows that the singly gold-attached angiotensin II consists 
of two species. One species has the gold bonded through the 
Arg (e.g., b2, b4, and b5 ions in Figure 5b) and the other has the 
gold bonded through His residue (e.g., y3, y4, and y5 ions in 
Figure 5b). Since the charge is retained near the N-terminus of 
the first species and C-terminus of the second species, the CID 
mass spectra is dominated by b-type and y-type fragment ions 
in the first and second species, respectively. Doubly gold-
attached angiotensin II consists of only one species with one 
gold chelated with Arg and the other with His (e.g., b2, y4, and 
y5 ions in Figure 5c).  
     The reaction solution of gold ion and angiotensin II is 
digested with trypsin to produce gold ion–angiotensin IV 
(VYIHPF) complex. MALDI-TOF MS and CID mass spectra 
(MALDI-TOF/TOF) of intact and singly gold-attached 
Angiotensin IV are shown in Figure S7 in Supplementary 
Material. Since there is only one gold binding residue His in 
angiotensin IV, as expected, the data interpretation is much 
simpler and it is in agreement with the conclusion that His 
(e.g., y3, a4, and y5 ions in Figure S7c in Supplementary 
Material) is the gold ion binding site for gold ion–angiotensin 
IV complexes. ESI-MS/MS (see Figure S8 in Supplementary 
Material) CID data on singly and doubly charged intact and 
singly gold-attached angiotensin IV further confirms this 
conclusion. Interestingly, doubly gold-attached of neither 
VYIHPF or VYIHPFHL is detected in this study. Unlike 
angiotensin I and II situation described above, additional His 
residue in VYIHPFHL does not promote additional gold ion 
attachment. 
 
 
Au Ion– CysAngiotensin II Complexes 
 
Evidence indicates that sulfhydryl group of Cys is an important 
Cu2+, Zn2+, and Hg2+ anchoring site of peptides [43, 64, 65] and 
gold ion binding site of proteins [14, 28, 50, 51]. 
CysAngiotensin II (CDRVYIHPF) is synthesized and its 
interaction with gold ions is probed by MS. MALDI-TOF MS 
(Figure 6a) of the reaction solution containing CysAngiotensin 
II in 1 mM AuCl3 or AuCl showed predominately singly 
charged intact (m/z 1149.55; abundant), singly gold-attached 
[M+Au(I)]+ (m/z 1345.52; less abundant), and doubly gold-
attached [M+2Au(I)]+ (m/z 1541.48; abundant) CysAngiotensin 
II ions. Similar to the MALDI-TOF MS data, ESI-MS (see 
Figure S9 in Supplementary Material) shows predominately the 
intact (singly charged, m/z 1149.55; doubly charged, m/z 
575.28), singly gold-attached [M+Au(I)+ (e – 1) H]e+ (singly 
charged, m/z 1345.52.; doubly charged, m/z 673.27), and 
doubly gold-attached [M+ 2Au(I)+ (e – 2) H]e+ (singly charged, 
m/z 1541.48; doubly charged, m/z 771.24) angiotensin II ions. 
Interestingly, the gold ion exists predominately in oxidation
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Figure 5. MS of angiotensin II in the presence of 1mM AuCl3: (a) MALDI-TOF MS; (b) CID mass spectrum (MALDI-TOF/TOF) of 
[M+Au(I)]+; and (c) CID mass spectrum (MALDI-TOF/TOF) of [M – H+2Au(I)]+ 
 
state of +I for gold-attached CysAngiotensin II with either 
AuCl3 or AuCl. The ESI condition seems to stabilize the 
gold(I) and promote the reduction of Au(III) to Au(I) probably 
by oxidizing the sulfhydryl group of Cys. The oxidized 
products of Cys are clearly present in Figure 6a at m/z 1165.55 
(convert cysteine to the corresponding sulfenic acid), m/z 
1181.55 (convert cysteine to the corresponding sulfinic acid), 
and to a lesser extent m/z 1197.55 (convert cysteine to the 
corresponding sulfonic acid). The relationship between relative 
abundance of the gold-attached ion species and concentration 
of AuCl3 or AuCl is similar as in angiotensin I described above. 
     The gold anchoring sites are identified as Cys, Arg, and His 
by CID mass spectra of singly and multiply charged intact, 
singly gold-bound, and doubly gold-bound CysAngiotensin II 
(Figure 6b–d and Figure S10 in Supplementary Material). An 
additional immonium ion detected at m/z 76, beside the 
immonium ions from Angiotensin II, in MALDI-TOF/TOF 
unambiguously identified the presence of Cys residue. As 
expected, data shows that the singly gold-attached 
CysAngiotensin II consists of three species. One species has 
the gold bonded through the residue Cys (e.g., b2, RVYIH, and  
y7 ions in Figure 6c), most likely through the sulfur group, and 
the other two species have the gold bonded through the residue 
Arg (e.g., DR(Au)VY ion in Figure 6c) and residue His (e.g., 
y3, y5, and y7 ions in Figure 6c), respectively. Data for the 
doubly gold-attached CysAngiotensin II also shows three 
species [gold bonded through both Cys and Arg (e.g., b3, y3, 
and b5 ions in Figure 6d), gold bonded through both Cys and 
His (e.g., RVY ion in Figure 6d), and gold bonded through the 
Arg and His (e.g., y8-H2O ion in Figure 6d)]. ESI-MS/MS (see 
Figure S10 in Supplementary Material) CID data on singly and 
doubly charged intact, singly gold-attached, and doubly gold-
attached CysAngiotensin II further supports the conclusion. To 
further confirm the importance of the Cys in gold binding, CID 
(MALDI-TOF/TOF) mass spectra are obtained with a simple 
synthetic tripeptide CDR and its gold complex to facilitate the 
data interpretation. The CID data of the intact, singly gold-
bound (y1, y2, and a3 ions in Figure S11 in Supplementary 
Material), and doubly gold-bound (y1, y2, and a3 ions in Figure 
S11 in Supplementary Material) tripeptide CDR indicates that 
Arg and Cys are the gold bonding sites and not the NH2-
terminal amino group or Asp. 
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Figure 6. Mass spectra of CysAngiotensin II in the presence of 1mM AuCl3: (a) MALDI-TOF mass spectrum; (b) CID mass 
spectrum (MALDI-TOF/TOF) of [M+H]+; (c) CID mass spectrum (MALDI-TOF/TOF) of [M+Au(I)]+; (d) CID mass spectrum 
(MALDI-TOF/TOF) of [M – H+2Au(I)]+ 
 
Conclusions 
 
MADLI-TOF MS and ESI-MS are used successfully to obtain 
valuable information about the interaction between gold ion 
and angiotensin peptides. Data shows singly/multiply charged 
ions of gold ion–angiotensin peptide complexes, which are 
represented as [peptide+a Au(I)+b Au(III)+ (e – a –3b) H]e+, 
where a,b≥0 and e is charge. Higher amount of the gold ion–
angiotensin peptide complexes occurs with higher AuCl or 
AuCl3 concentration. However, too high a gold concentration 
encourages aggregation and/or precipitation of gold–peptide 
complex. Tandem MS data shows that Cys, His, and Arg 
residues of the peptide seem to be the preferred anchoring sites 
for gold ion, and the gold– peptide bond is strong enough to 
survive the CID process. This study reveals that MALDI-TOF 
MS mainly detects singly charged Au(I)–peptide complexes, 
indicating that ion formation by MALDI process promotes the 
reduction of Au(III) to Au(I). In addition, ESI-MS data shows 
that gold ion in the gold ion-angiotensin peptide complexes 
exists in oxidation state of I and/or III, depending on the 
peptide used. Redox processes are not uncommon for gold ion–
peptide systems and gold ion containing compounds [28, 66–
68]. Gold ions in the Au–angiotensin II and Au–
CysAngiotensin II complexes exit primarily in oxidation state 
of III and I, respectively. The detection of the formation of 
different gold ion–angiotensin peptide complexes with different 
abundances suggests that gold containing anticancer drugs may 
interact differently with various peptides/proteins. This may 
alter functions of peptides/proteins, which inhibits the 
proliferation and differentiation of tumor cells. MS studies on 
interactions between gold ion and bigger peptides/proteins, gas-
phase disulfide bridge cleavages with gold [53, 54], and 
catalytic reactions by gold [69] are underway in this laboratory. 
 
Acknowledgments 
 
The authors gratefully acknowledge the support of the 
Research Resources Center at the University of Illinois, 
Chicago. 
 
 
 
 
 
 
 
 
 
J. Lee et al.: Gold Ion–Peptide Interaction        
                                                                  
References 
 
1. Kelland, L.: The Resurgence of Platinum-Based Cancer Chemotherapy. 
Nature Rev Cancer 7, 573–584 (2007) 
2. Alderden, R.A., Hall, M.D., Hambley, T.W.: The Discovery and 
 Development of Cisplatin. J. Chem. Ed 83, 728–734 (2006) 
3. Lovejoy, K.S., Lippard, S.J.: Non-Traditional Platinum Compounds for 
Improved Accumulation, Oral Bioavailability, and Tumor Targeting. 
 Dalton Trans. 10651–10659 (2009) 
4. Garbutcheon-Singh, K.B.: Grant M.P, Harper B.W., Krause-Heuer A.  
 M., Manohar M., Orkey N., Aldrich-Wright J.R.: Transition metal 
 based anticancer drugs. Curr. Top. Med. Chem. 11, 521–542 (2011) 
5. Bergama, A., Sava, G.: Ruthenium Anticancer Compounds: Myths and 
 Realities of the Emerging Metal-Based Drugs. Dalton Trans. 40, 7817– 
 7823 (2011) 
6. Wang, C., Shih, W., Chang, H., Kuo, Y., Hung, W., Ong, T., Li, W.: 
 Preparation and Characterization of Amino-Linked Hetercyclic Carbene 
 Pelladium, Gold, and Silver Complexes and Their Use as Anticancer 
 Agents that Act by Triggering Apoptotic Cell Death. J. Med. Chem. 54, 
 5245–5249 (2011) 
7. Milacic, V., Fregona, D., Dou, Q.P.: Gold Complexes as Prospective 
 Metal-based Anticancer Drugs. Histol Histopathol. 23, 101–108 (2008) 
8. Sun, R., Li, C., Ma, D., Yan, J., Lok, C., Leung, C., Zhu, N., Che, C.: 
 Stable Anticancer Gold(III)-porphyrin Complexes: Effects of Porphyrin 
 Structure. Chemistry 16, 3097–3113 (2010) 
9. Ronconi, L., Aldinucci, D., Dou, Q.P., Fregona, D.: Latest Insights into 
 the Anticancer Activity of Gold(III)-dithiocarbamato Complexes. 
 Anticancer Agents Med. Chem. 10, 283–292 (2010) 
10. Chow, K.H., Sun, R., Lam, J., Li, C., Xu, A., Ma, D., Abagyan, R., 
   Wang, Y., Che, C.: A Gold(III) Porphyrin Complex with Antitumor 
   Properties Targets the Wnt/ β-catenin Pathway. Cancer Res. 70, 329– 
   337 (2010) 
11. Tu, S., Sun, W.R., Lin, M., Tao, C.J., Zou, B., Gu, Q., Kung, H., Che, 
   C., Wong, B.: Gold (III) Porphyrin Complexes Induce Apoptosis and 
   Cell Cycle Arrest and Inhibit Tumor Growth in Colon Cancer. Cancer 
   115, 4459–4469 (2009) 
12. Ott, I.: On the Medicinal Chemistry of Gold Complexes as Anticancer 
   Drugs. Coord. Chem. Rev. 253, 1670–1681 (2009) 
13. Sun, R.W., Che, C.: The Anti-cancer Properties of Gold(III) Compounds 
    with Dianionic Porphyrin and Tetradentate Ligands. Coord. Chem. Rev. 
   253, 1682–1691 (2009) 
14. Bindolia, A., Maria Pia Rigobello, M.P., Scutari, G., Gabbiani, C., 
   Casini, A., Messori, L.: Thioredoxin Reductase: A Target for Gold 
   Compounds Acting as Potential Anticancer Drugs. Coord. Chem. Rev 
   253, 1692–1707 (2009) 
15. Milacic, V., Dou, Q.P.: The Tumor Proteasome as a Novel Target for 
   Gold(III) Complexes: Implications for Breast Cancer Therapy. Coord. 
   Chem. Rev. 253, 1649–1660 (2009) 
16. Gabbiani, C., Casini, A., Messori, L.: Gold (III) Compounds as 
   Anticancer Drugs. Gold Bulletin 40, 73–81 (2007) 
17. Messori, L., Marcon, G., Cinellu, M., Agostina, M., Coronnello, M., 
   Mini, E., Gabbiani, C., Chiara, Q., Orioli, P., Pierluigi, P.: Solution 
   Chemistry and Cytotoxic Properties of Novel Organogold (III) 
   Compounds. Bioorg. Med. Chem. 12, 6039–6043 (2004) 
18. Messori, L., Marcon, G., Orioli, P.: Gold (III) Compounds as New 
   Family of Anticancer Drugs. Bioinorg. Chem. Appl. 1, 177–187 
   (2003) 
19. Yang, T., Tu, C., Zhang, J., Lin, L., Zhang, X., Liu, Q., Ding, J., 
   Xu, Q., Guo, Z.J.: Novel Au (III) Complexes of Aminoquinoline 
   Derivatives: Crystal Structure, DNA Binding and Cytotoxicity 
   Against Melanoma and Lung Tumour Cells. Chem. Soc., Dalton 
   Trans. 17, 3419–3424 (2003) 
20. Marcon, G., Messori, L., Orioli, P.: Gold (III) Complexes as a New 
   Family of Cytotoxic and Antitumor Agents. Exp. Rev. Antican. Ther. 2, 
   337–346 (2002) 
 
21. Chapkanov, A., Miteva, Y., Kolev, T., Spiteller, M., Koleva, B.: New 
   Au (III), Pt (II) and Pd (II) Complexes with Pentapeptide Glycyl-glycyl- 
   (L)-methyonyl-glycyl-glycine and Their Interaction with Calf Thymus 
   DNA. Protein Pept Lett. 17, 228–237 (2010) 
22. Kolev, T.S., Koleva, B.B., Zareva, S.Y., Spiteller, M.: Au (III)- 
   complexes of the Alanyl-containing Peptides Glycylalanine and 
   Glycylalanylalanine–Synthesis, Spectroscopic and Structural     
     Characterization. Inorg. Chim. Acta 359, 4367–4376 (2006) 
23. Kolev, T., Ivanova, B.B., Zareva, S.Y.: An Au(III) Complex of GlycylS 
   serine: a Linear Polarized IR and 1H- and 13C-NMR Investigation. J. 
   Coord. Chem. 60, 109–115 (2007) 
24. Koleva, B.B., Kolev, T., Zareva, S.Y., Spiteller, M.: The Dipeptide 
   Alanylphenylalanine (H-Ala-Phe-OH)–Protonation and Coordination 
   Ability with Au (III). J. Mol. Struct. 831, 165–173 (2007) 
25. Ivanova, B.B.: Solid-state Linear-dichroic Infrared Spectroscopic 
   Analysis of the Dipeptide S-Phe–S-Phe and Its Mononuclear Au (III) 
   Complex. J. Coord. Chem. 58, 587–593 (2005) 
26. Wienken, M., Lippert, B., Zangrando, M., Randaccio, L.: Glycyl-Lhistidine 
    Dipeptide Complexes. Preparation and X-ray Structures of Monomeric and 
   Cyclic Tetrameric Species. Inorg. Chem. 31, 1983–1985 (1992) 
27. Best, S.L., Chattopadhyay, T.K., Djuran, M.I., Palmer, R.A., Sadler, 
   P., Sovago, I., Varnagy, M.: Gold(III) and Palladium(II) Complexes 
   of Glycylglycyl-L-histidine: Crystal Structures of [AuIII(Gly-Gly-LHis-H-  
   2)]Cl xH2O and [PdII(Gly-Gly-L-His-H-2)]x1.5H2O and His 
   ε- NH Deprotonation. J. Chem. Soc., Dalton Trans 15, 2587–2596 
   (1997) 
28. Mendes, F., Groessl, M., Nazarov, A.A., Tsybin, Y.O., Sava, G., Santos, I., 
   Dyson, P.J., Casini, A.: Metal-Based Inhibition of Poly(ADP-ribose) 
   Polymerase –The Guardian Angel of DNA. J. Med. Chem. 54, 2196–2206 
   (2011) 
29. Whitehouse, C.M., Dreyer, R.N., Yamashita, M., Fenn, J.B.: Electrospray 
   Interface for Liquid Chromatographs and Mass Spectrometers.Anal. Chem. 
   57, 675–679 (1985) 
30. Banks Jr., J.F., Whitehouse, C.M.: Electrospray Ionization Mass 
   Spectrometry. Methods Enzymol. 270, 486–519 (1996) 
31. Karas, M., Hillenkamp, F.: Laser Desorption Ionization of Proteins with 
   Molecular Masses Exceeding 10 000 Daltons. Anal. Chem 60, 2299– 
   2301 (1988) 
32. Beavis, R.C., Chait, B.T.: Matrix-Assisted Laser Desorption Ionization 
   Mass Spectrometry of Proteins. Methods Enzymol 270, 519–551 (1996) 
33. Schalley, C.A., Springer, A.: Noncovalent Complexes with peptides and 
   Proteins. Mass Spectrometry and Gas-Phase Chemistry of Noncovalent 
   Complexes, pp. 359–422. John Wiley and Sons, Hoboken, NJ (2009) 
34. Wu, Z., Fernandez-Lima, F.A., Perez, L.M., Russell, D.H.: A New 
   Copper Containing MALDI Matrix That Yields High Abundances of 
   [Peptide + Cu]+ Ions. J. Am. Soc. Mass Spectrom. 20, 1263–1271 
   (2009) 
35. Wyttenbach, T., Liu, D., Bowers, M.T.: Interactions of the Hormone 
    Oxytocin with Divalent Metal Ions. J. Am. Chem. Soc. 130, 5993–6000 
   (2008) 
36. Schafer, M., Dreiocker, F., Budzikiewicz, H.: Collision-induced Loss of 
   Ag+ Adducts of Alkylamines, Aminocarboxylic Acids, and Alkyl 
   Benzyl Ethers Lead Exclusively to thermodymanically favored Product 
   Ions. J. Mass Spectrom. 44, 278–284 (2009) 
37. Li, H.B., Siu, K.W.M., Guevremont, R., LeBlanc, J.C.Y.: Complexes of 
   Silver(I) With Peptides and Proteins as Produced in Electrospray Mass 
   Spectrometry. J. Am. Soc. Mass Spectrom. 8, 781–792 (1997) 
38. Liu, H., Håkansson, K.: Divalent Metal Ion–Peptide Interactions Probed 
   by Electron Capture Dissociation of Trications. J. Am. Soc. Mass 
   Spectrom. 17, 1731–1741 (2006) 
39. Lagarrigue, M., Bosse´e, A., Afonso, C., Fournier, F., Bellier, B., Tabet, 
   J.: Diastereomeric Differentiation of Peptides with CuII and FeII 
   Complexation in an Ion Trap Mass Spectrometer. J. Mass Spectrom. 
   41, 1073–1085 (2006) 
 
 
J. Lee et al.: Gold Ion–Peptide Interaction        
                                                                  
40. Bluhm, B.K., Shields, S.J., Bayse, C.A., Hall, M.B., Russell, D.H.: 
   Determination of Copper Binding Sites in Peptides Containing Basic 
   Residues: Combined Experimental and Theoretical Study. Int. J. Mass 
   Spectrom. 204, 31–46 (2001) 
41. Shields, S.J., Bluhm, B.K., Russell, D.H.: Novel Method for [M + Cu]+ 
   Ion Formation by Matrix-Assisted Laser Desorption Ionization. Int. J. 
   Mass Spectrom. 183, 185–195 (1999) 
42. Wong, C.K.L., Chan, T.W.D.: Cationization Processes in MatrixAssisted 
   Laser Desorption/Ionization Mass Spectrometry: Attachment 
   of Divalent and Trivalent Metal Ions. Rapid Commun. Mass Spectrom. 
   11, 513–519 (1997) 
43. D'Agostino, A., Colton, R., Traeger, J.C., Canty, A.J.: An Electrospray 
   Mass-Spectrometric Study of Organomercury(II) and Mercuric interactions 
   with Peptides Involving Cysteinyl Ligands. Eur. Mass Spectrom. 2, 273– 
   285 (1996) 
44. Hu, P.F., Gross, M.L.: Gas-phase Interactions of Transition-metal Ions 
   and Di- and Tripeptides: A Comparison with Alkaline-earth-metal-ion 
   Interactions. J. Am. Chem. Soc. 115, 8821–8828 (1993) 
45.  Hu, P.F., Loo, J.A.: Gas Phase Coordination Properties of Co2+ and Ni2+ 
    with Histine-containing Peptides. J. Am. Chem. Soc. 117, 11314–11319 
   (1995) 
46. Reiter, A., Adams, J., Zhao, H.: Intrinsic (Gas-Phase) Binding of Co2+ and 
   Ni2+ by Peptides—A Direct Reflection of Aqueous-Phase Chemistry. J. 
   Am. Chem. Soc. 116, 7827–7838 (1994) 
47. Cerda, B., Conett, L., Wesdemiotis, C.: Probing the Interaction of 
      Alkali and Transition Metal Ions with Bradykinin and its DesArginine      
    derivatives via Matrix-Assisted Laser Desorption/Ionization and Postsource  
   Decay Mass Spectrometry. Int. J. Mass Spectrom. 193, 205–226 (1999) 
48. Loo, J.A., Hu, P.: Interaction of Angiotensin peptides and Zinc Metal 
    Ions Probed by Electrospray Ionization Mass Spectrometry. J. Am. Soc. 
   Mass Spectrom. 5, 959–965 (1994) 
49. Pacheco, E.A., Tiekink, E.R.T., Whitehouse, M.W.: Gold Compounds 
   and Their Applications in Medicine. Gold Chemistry: Applications and 
   Future Directions in the Life Sciences, pp. 283–319. Wiley-VCH 
   Verlag GmbH & Co. KgaA, Weinheim, Germany (2009) 
50. Deponte, M., Urig, S., Arscott, L.D., Fritz-Wolf, K., Re´au, R., 
   HeroldMende, C., Koncarevic, S., Meyer, M., Davioud-Charvet, E., Ballou, 
   D.P., Williams, C.H., Katja Becker, K.: Mechanistic Studies on a Novel,   
   Highly Potent Gold-phosphole Inhibitor of Human Glutathione Reductase.   
      J. Biol. 
   Chem. 280, 20628–20637 (2005) 
51. Talib, J., Beck, J.L., Ralph, S.F.: A Mass Spectrometric Investigation of 
    the Binding of Gold Antiarthritic Agents and the Metabolite [Au(CN)2] 
   to Human Serum Albumin. J. Biol. Inorg. Chem. 11, 559–570 (2006) 
52. Zou, J., Tayor, P., Dornan, J., Robinson, S.P., Walkinshaw, M.D., 
   Salder, P.J.: First Crystal Structure of a Medicinally Relevant Gold 
   Protein Complex: Unexpected Binding of [Au(Pet3)]+ to Histidine. 
   Angew. Chem. Int. Ed. 39, 2931–2934 (2000) 
53. Lioe, H., Duan, M., O'Hair, R.A.J.: Can Metal Ions be Used as Gas 
   Phase Disulfide Bond Cleavage Reagents? A Survey of Coinage Metal 
   Complexes of Model Peptides Containing an Intermolecular Disulfide 
   Bond. Rapid Commun. Mass Spectrom. 21, 2727–2733 (2007) 
54. Gunawardena, H.P., O'Hair, R.A.J., McLuckey, S.A.: Selective 
   Disulfide Bond Cleavage in Gold (I) Cationized Polypeptide Ions 
   Formed via Gas-Phase Ion/Ion Cation Switching. J. Proteome Res. 
   5, 2087–2092 (2006) 
55. Karas, M., Kruger, R.: Ion Formation in MALDI: The Cluster 
   Ionization Mechanism. Chem. Rev. 103, 427–439 (2003) 
56. Schwerdtfeger, P., Lein, M.: Theoretical Chemistry of Gold—from 
   Atoms to Molecules, Clusters, Surfaces, and the Solid State. Gold 
   Chemistry: Applications and Future Directions in the Life Sciences. 
   Wiley-VCH Verlag GmbH & Co. KGaA: Weinheim, Germany; pp. 
   183–246 (2009) 
 
 
 
57. Trimpin, S., Ren, Y., Wang, B., Lietz, C.B., Richards, A.L., Marshall, 
   D.D., Inutan, E.D.: Extending the Laserspray Ionization Concept to 
   Produce Highly Charged Ions at High Vacuum on a Time-of-Flight 
   Mass Analyzer. Anal. Chem 15, 5469–5475 (2011) 
58. Karas, M., Gluckmann, M., Schafer, J.: Ionization in Matrix-Assisted 
   Laser Desorption/Ionization: Singly Charged Molecular Ions are the 
   Lucky Survivors. J. Mass Spectrum. 35, 1–12 (2000) 
59. Medzihradszky, K.F.: Peptide Sequence Analysis. Methods Enzymol. 
   402, 209–244 (2005) 
60. Paizs, B., Suhai, S.: Fragmentation Pathways of Protonated Peptides. 
   Mass. Spectrom. Rev. 24, 508–548 (2005) 
61. Wells, J.M., McLuckey, S.A.: Collision-Induced Dissociation (CID) of 
   Peptides and Proteins. Methods Enzymol. 402, 148–185 (2005) 
62. Best, S.L., Chattopadhyay, T.K., Djuran, M.I., Palmer, R.A., Salder, P.J., 
   Sovago, I., Varnagy, M.: Gold(III) and Palladium(II) Complexes of 
   Glycylglycyl-L-Histidine: Crystal Structures of [AuIII(Gly-Gly-L-His-H-    
      2)]Cl·H2 and [PdII(Gly-Gly-L-His-H-2)]·1.5H2 and HisεNH           
     deprotonation. J. Chem. Soc., Dalton Trans. 15, 2587–2596 (1997) 
63. Sigel, H., Martin, R.B.: Coordinating Properties of the Amide Bond. 
   Stability and Structure of Metal Ion Complexes of Peptides and Related 
   Ligands. Chem. Rev. 82, 385–426 (1982) 
64. Hutchens, T.W., Allen, M.H., Li, C.M., Yip, T.: Occupancy of a C2-C2 
   Type “Zinc-Finger” Protein Domain by Copper. Direct Observation by 
   Electrospray Ionization Mass Spectrometry. FEBS Lett. 309, 170–174 
   (1992) 
65. Hutchens, T.W., Allen, M.H.: Electrospray Ionization Mass Spectrometry 
   for the Detection of Discrete Peptide/Metal-Ion Complexes Involving 
   Multiple Cysteine (Sulfur) Ligands. Rapid Commun. Mass Spectrom. 6, 
   308–312 (1992) 
66. Casini, A., Cinellu, M.A., Minghetti, G., Gabbiani, C., Coronnello, M., 
   Mini, E., Messori, L.: Structural and Solution Chemistry, Antiproliferative 
   Effects, and DNA and Protein Binding Properties of a Series of Dinuclear 
   Gold(III) Compounds with Bipyridyl Ligands. J. Med. Chem. 49, 5524– 
   5531 (2006) 
67. Gimeno, M.C.: The Chemistry of Gold. Modern Supramolecular Gold 
   Chemistry: Gole-Metal Interactions and Applications, pp. 1–63. WileyVCH  
   Verlag GmbH & Co. KGaA, Weinheim, Germany (2008) 
68. Puddephatt, R.J.: The Chemistry of Gold. Elsevier, New York (1978) 
69. Lein, M., Rudolph, M., Hashmi, S.K., Schwerdtfeger, P.: Homogeneous 
   Gold Catalysis through Relativistic Effects: Addition of Water to 
   Propyne. Organometallics 29, 2206–2210 (2010) 
